Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ISRCTN26002902
ISRCTN26002902Completed未知

Intra-coronary transfusion of autologous CD34+ cells improves left ventricular function in patients with diffuse coronary artery disease and non-candidates for coronary artery intervention: a randomized placebo controlled trial

ational Science Council (Taiwan)0 sites60 target enrollmentStarted: September 11, 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
60
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

2015 results in http://www.ncbi.nlm.nih.gov/pubmed/26154930 2020 results in https://pubmed.ncbi.nlm.nih.gov/32272750 (added 15/04/2020) 2020 results in https://pubmed.ncbi.nlm.nih.gov/32727585/ (added 17/12/2020)

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Patients with age between 20-80 years-old who have angina pectoris resulted in severely and diffusely atherosclerotic obstructive CAD with refractory to optimal medication are not the candidates for both PCI or CABG

Exclusion Criteria

  • •1. Age less than 20 years or more than 80 years
  • •2. Pregnant women
  • •3. Patients with adventitious agents (like HIV, Hepatitis viruses)
  • •4. Myocardial infarction (MI) within 3 months
  • •5. Aortic stenosis or mitral stenosis
  • •6. Congestive heart failure, New York Heart Association functional class (NYHA Fc.)IV
  • •7. Malignancy or other severe disease with life span less than one year
  • •8. Chronic kidney disease with CCr<20ml/min and end stage renal disease

Investigators

Sponsor
ational Science Council (Taiwan)

Similar Trials

Completed
Not Applicable
Intra-coronary transfusion of autologous CD34+ cells improves left ventricular function in patients with diffuse coronary artery disease and non candidates for coronary artery interventioChronic ischemic heart diseaseCirculatory SystemChronic ischaemic heart disease, unspecified
ISRCTN72853206ational Science Council (Taiwan)38
Completed
Phase 1
Autologous peripheral blood-derived CD34+ cell transplantation for acute kidney injury.acute kidney injury
JPRN-UMIN000031691Kidney Disease and Transplant Center, Shonan Kamakura General Hospital9
Completed
Phase 1
CD133+ Autologous Cells After Myocardial InfarctionAcute Myocardial Infarction
NCT00400959Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico15
Completed
Phase 1
A Phase I/ II Clinical Trial: Autologous CD34+ Cell Transplantation for Bone and Vascular Healing in Patients with Non-Union Fractureon-Union Fracture
JPRN-UMIN000002993Ryosuke Kuroda, M.D., Ph.D.17
Active, not recruiting
Phase 1
A study testing a gene therapy to treat mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A)
EUCTR2019-002051-42-GBniversity of Manchester5